Literature DB >> 26456577

Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.

Roberto Würth1, Stefano Thellung1, Adriana Bajetto1, Michele Mazzanti2, Tullio Florio1, Federica Barbieri3.   

Abstract

Drug repositioning is gaining increasing attention in drug discovery because it represents a smart way to exploit new molecular targets of a known drug or target promiscuity among diverse diseases, for medical uses different from the one originally considered. In this review, we focus on known non-oncological drugs with new therapeutic applications in oncology, explaining the rationale behind this approach and providing practical evidence. Moving from incompleteness of the knowledge of drug-target interactions, particularly for older molecules, we highlight opportunities for repurposing compounds as cancer therapeutics, underling the biologically and clinically relevant affinities for new targets. Ideal candidates for repositioning can contribute to the therapeutically unmet need for more-efficient anticancer agents, including drugs that selectively target cancer stem cells.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26456577     DOI: 10.1016/j.drudis.2015.09.017

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  49 in total

1.  Emetine induces estrogen receptor alpha degradation and prevents 17β-estradiol-induced breast cancer cell proliferation.

Authors:  Claudia Busonero; Stefano Leone; Filippo Acconcia
Journal:  Cell Oncol (Dordr)       Date:  2017-03-29       Impact factor: 6.730

Review 2.  Current status and contemporary approaches to the discovery of antitumor agents from higher plants.

Authors:  Garima Agarwal; Peter J Blanco Carcache; Ermias Mekuria Addo; A Douglas Kinghorn
Journal:  Biotechnol Adv       Date:  2019-01-08       Impact factor: 14.227

3.  Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma.

Authors:  Yi Luo; Anqi Zeng; Aiping Fang; Linjiang Song; Chen Fan; Chenjuan Zeng; Tinghong Ye; Hao Chen; Chongqi Tu; Yongmei Xie
Journal:  Invest New Drugs       Date:  2019-01-25       Impact factor: 3.850

4.  Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

Authors:  Lian-Xiang Luo; Xing-Xing Fan; Ying Li; Xia Peng; Yin-Chun Ji; Wendy Wen-Luan Hsiao; Liang Liu; Elaine Lai-Han Leung; Xiao-Jun Yao
Journal:  Medchemcomm       Date:  2017-01-26       Impact factor: 3.597

5.  Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

Authors:  Robert S Kerbel
Journal:  Neuro Oncol       Date:  2016-01-31       Impact factor: 12.300

Review 6.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

Review 7.  Turning liabilities into opportunities: Off-target based drug repurposing in cancer.

Authors:  Vinayak Palve; Yi Liao; Lily L Remsing Rix; Uwe Rix
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

8.  Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.

Authors:  Xiuman Zhou; Ling Jiao; Yuzhen Qian; Qingyu Dong; Yixuan Sun; Wei V Zheng; Wenshan Zhao; Wenjie Zhai; Lu Qiu; Yahong Wu; Hongfei Wang; Yanfeng Gao; Junhui Chen
Journal:  Biomolecules       Date:  2021-05-10

9.  Artemisinin Derivatives Inhibit Non-small Cell Lung Cancer Cells Through Induction of ROS-dependent Apoptosis/Ferroptosis.

Authors:  Qiuting Zhang; Huimei Yi; Hui Yao; Lu Lu; Guangchun He; Mi Wu; Chanjuan Zheng; Ying Li; Sisi Chen; Lewei Li; Hongyuan Yu; Guifei Li; Xiaojun Tao; Shujun Fu; Xiyun Deng
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

Review 10.  Drug rechanneling: A novel paradigm for cancer treatment.

Authors:  Itishree Kaushik; Sharavan Ramachandran; Sahdeo Prasad; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2020-05-11       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.